newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with